Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.

Can Fam Physician

Assistant Professor in the School of Epidemiology, Public Health and Preventive Medicine, Deputy Director of the Centre for Global Health at the University of Ottawa, and a clinical epidemiology methodologist at the Bruyère Research Institute.

Published: November 2017

AI Article Synopsis

  • Developed an evidence-based guideline to assist clinicians in safely tapering, stopping, or switching antihyperglycemic agents for older adults.
  • The process involved a team of healthcare professionals using the GRADE approach and systematic reviews to assess the benefits and harms of deprescribing these medications.
  • The guidelines emphasize personalized care, recommending the deprescribing of medications that may cause hypoglycemia or other adverse effects, especially for frail patients, those with dementia, or limited life expectancy.

Article Abstract

Objective: To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper, stop, or switch antihyperglycemic agents in older adults.

Methods: We focused on the highest level of evidence available and sought input from primary care professionals in guideline development, review, and endorsement processes. Seven clinicians (2 family physicians, 3 pharmacists, 1 nurse practitioner, and 1 endocrinologist) and a methodologist comprised the overall team; members disclosed conflicts of interest. We used a rigorous process, including the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, for guideline development. We conducted a systematic review to assess evidence for the benefits and harms of deprescribing antihyperglycemic agents. We performed a review of reviews of the harms of continued antihyperglycemic medication use, and narrative syntheses of patient preferences and resource implications. We used these syntheses and GRADE quality-of-evidence ratings to generate recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and stakeholders for review and revisions were made at each stage. A decision-support algorithm was developed to accompany the guideline.

Recommendations: We recommend deprescribing antihyperglycemic medications known to contribute to hypoglycemia in older adults at risk or in situations where antihyperglycemic medications might be causing other adverse effects, and individualizing targets and deprescribing accordingly for those who are frail, have dementia, or have a limited life expectancy.

Conclusion: This guideline provides practical recommendations for making decisions about deprescribing antihyperglycemic agents. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685444PMC

Publication Analysis

Top Keywords

deprescribing antihyperglycemic
16
antihyperglycemic agents
16
agents older
8
guideline development
8
antihyperglycemic medications
8
guideline
7
antihyperglycemic
6
deprescribing
5
agents
4
older persons
4

Similar Publications

Unlabelled: Diabetes caused 6.7 million deaths in 2021, equating to one death every five seconds, with its global financial burden projected to rise from $1.32 trillion in 2015 to $2.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical practice guidelines (CPGs) for diabetes management face challenges in older adults due to factors like frailty and multiple health issues.
  • * The systematic review analyzed 23 CPGs from the last decade, focusing on HbA1c targets and treatment recommendations for older and frail individuals.
  • * Results showed most CPGs recommend stricter HbA1c targets for healthier older adults, while suggesting more lenient targets for frail individuals, though there's variability in pharmacotherapy advice, especially for frail patients.
View Article and Find Full Text PDF

[Not Available].

CMAJ

August 2024

Hôpital Women's College et University of Toronto (Lega, McCarthy), Toronto, Ont.; University of British Columbia (Thompson), Vancouver, C.-B.; Trillium Health Partners (McCarthy), Institute for Better Health, Toronto, Ont.

View Article and Find Full Text PDF

Introduction: For people with type 2 diabetes and/or cardiovascular conditions, deprescribing of glucose-lowering, blood pressure-lowering and/or lipid-lowering medication is recommended when they age, and their health status deteriorates. So far, deprescribing rates of these so-called cardiometabolic medications are low. A review of challenges and interventions addressing these challenges in this population is pertinent.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!